AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Evolution of the Initial Distribution Volume of Glucose in the Severe Burned Adults

RecruitingPhase 2Ages 18 Years - anyAllCentre Hospitalier Régional Metz-Thionville
💬

In plain words

What the trial is, and whether it could suit you

This is a prospective, observational, monocentric, phase II (exploratory) cohort study aiming to describe the evolutionary profile of the initial volume of glucose distribution (IDVG) during the first four days of management of severely burned patient.

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * Patients over 18 years of age * Patients hospitalized with burns of at least 30% of body surface area * By a thermal mechanism * At the CHR Metz-Thionville burn center * managed within the 8 hours post-burn * Patient affiliated to a social security scheme * Written consent obtained from the patient (or from the trusted person, family or relatives if the patient is unable to sign/express consent) or emergency inclusion if the patient is unable to express consent and neither the trusted support person nor any member of the family or relatives is present at the time of inclusion. Exclusion Criteria: * Diabetic patients on insulin * Patient with a CONTRAINDICATION to GLUCOSE 30% PROAMP, solution for injection * Patients with pre-hospital cardiac arrest * extra corporeal circulation patient: Extra Corporeal Membranous Oxygenation (ECMO) or Extra Corporeal Life Support (ECLS) or CRRT (Continuous Renal Replacement Therapy) * patient without a central venous line or arterial catheter * Patient moribund or immediately subject to therapeutic limitation * Impossibility of trans-pulmonary thermodilution monitoring (vascular access difficulties) * Pregnant, parturient or breast-feeding women * Patient under guardianship, curatorship or safeguard of justice * Cognitive impairment or language barrier
💊

What it tests

  • Glucose 30% Intravenous Solution
📍

Where

1 site
CHR Metz-Thionville/Hopital de Mercy
Metz, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy